

# Author Index for Volume 13

- ACAPS Group, 293  
Ahn SA, 325  
AIDS Clinical Trials Group (ACTG), 22  
Allison MJ, 315  
Anderson B, 91  
Appel LJ, 240
- Bausell RB, 178  
Bigger JT, Jr, 466  
Birch R, 80, 156  
Blackhurst DW, 40  
Boichot HD, 325  
Bond MG, 495  
Bragg C, 156  
Branyon M, 466  
Bristol DR, 519  
Brown MB, 213  
Burchell HB, 185  
Byar DP, 6  
Byington RP, 495
- Caan B, 156  
Campion J, 466  
Cappelleri JC, 190  
Carew BD, 325  
Chalmers I, 100  
CHF STAT Investigators, 339  
Colling CL, 339  
Conlon M, 134  
Cooper E, 272  
Corle DK, 6  
Crouse JR, 495  
Cutter GR, 80
- Davis KB, 226  
de Pauw M, 351  
Deedwania P, 339  
Desu MM, 519  
Dickersin K, 170, 507  
Dierenfeldt BJ, 325  
Dolan NA, 325  
Dyer AR, 80
- Early Breast Cancer Trialists' Collaborative Group, 250  
Edens TR, 325  
Edler L, 517  
Eigo J, 272
- Ellenberg SS, 272, 513  
Espeland MA, 495
- Facey KM, 122  
Feussner JR, 321  
Finkelstein DM, 272, 513  
Fisher S, 339  
Fleiss JL, 466  
Fletcher RD, 339  
Freedman B, 1  
Furberg CD, 495
- Gail MH, 6  
Garcia-Lopez F, 507  
Goldman AI, 256  
Gorkin L, 466  
Greenberg H, 93
- Hallstrom AP, 148  
Handshaw K, 466  
Hawkins BS, 40  
Hertert S, 315  
Hill AB, 515  
Hill ID, 515  
Hillman DW, 256  
Hilner JE, 156  
Hoth DF, 272
- Jones DR, 459
- Kahn JO, 513  
Kershner RP, 248  
Kinney MR, 466
- Lachin JM, 62  
Lan S-P, 62  
Lewis D, 339  
Litwin PE, 148  
Lui K-J, 446  
Lupus Nephritis Collaborative Study Group, 62
- Machin D, 515  
Marwaha S, 240  
Massie B, 339  
McBride R, 487  
McDonald A, 156  
McGovern M, 495
- Nusinoff-Lehrman S, 272
- Olschewski M, 226  
Orr PR, 40  
Ottenbacher K, 50
- Paridaens R, 250  
Patel M, 240  
Pechacek TF, 6  
Perkins LL, 80  
Probstfield JL, 325
- Raghavarao D, 519  
Rennie D, 443  
Reynolds-Haertle RA, 487  
Rolnitzky LM, 466  
Ryan TJ, 253
- Sacks H, 272  
Savage PJ, 80  
Schoenfelder J, 351  
Schron E, 466  
Schumacher M, 226  
Shea S, 466  
Silverman WA, 97, 100  
Simel DL, 321  
Singh B, 339  
Singh S, 339  
Slattery ML, 156  
Smith JS, 181  
Smoak CG, 156  
Spilker B, 351  
Sprinkle JW, 495  
Studies of Ocular Complications of AIDS (SOCA) Research Group, 22
- Sylvester R, 91, 178
- Thomas RG, 134  
Trochim WMK, 190
- Van Horn L, 156  
Vollmar J, 517  
Vollmer WM, 315
- Wagenknecht LE, 80  
Weaver WD, 148  
Weiner DH, 325  
Whelton PK, 240  
Whitehead J, 106  
Wittes J, 156

---

## Subject Index for Volume 13

---

### ACUTE MYOCARDIAL INFARCTION

Thrombolytic Therapy for Acute  
Myocardial Infarction in the United  
States: We Started on the High  
Road, 253

### ADVERSE DRUG REACTIONS

The Future of Statistics and Statisticians in  
European Regulatory Affairs, 459

### AIDS

AIDS and the Ethics of Clinical Trials:  
Learning the Right Lessons, 1  
Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial: 1.  
Rationale, Design, and Methods, 22  
Studying Treatments for AIDS: New  
Challenges for Clinical Trials—A  
Panel Discussion at the 1990 Annual  
Meeting of the Society for Clinical  
Trials, 272

### AMIODARONE

Congestive Heart Failure: Survival Trial of  
Antiarrhythmic Therapy (CHF  
STAT), 339

### ANTIARRHYTHMIC DRUG THERAPY

Congestive Heart Failure: Survival Trial of  
Antiarrhythmic Therapy (CHF  
STAT), 339

### ANTI-THROMBOTIC AGENTS

Rationale and Design for the  
Asymptomatic Carotid Artery  
Plaque Study (ACAPS), 293

### ASYMPTOTIC VARIANCE

Sample Size Determination Under an  
Exponential Model in the Presence  
of a Confounder and Type I  
Censoring, 446

### ATHEROSCLEROSIS

Pravastatin, Lipids, and Atherosclerosis in  
the Carotid Arteries: Design Features  
of a Clinical Trial with Carotid Ath-  
erosclerosis Outcome, 495  
Rationale and Design for the  
Asymptomatic Carotid Artery

Plaque Study (ACAPS), 293

### BAYES ODDS RATIOS

Termination of a Clinical Trial With No  
Treatment Group Difference: The  
Lupus Nephritis Collaborative  
Study, 62

### BIAS

Patient and Clinical Factors Predictive of  
Missed Visits and Inactive Status in  
a Multicenter Clinical Trial, 40

### BLOOD PRESSURE MONITORING

The Impact of Automated Blood Pressure  
Devices on the Efficiency of Clinical  
Trials, 240

### BOOK REVIEWS

Advanced Research Methodology: An  
Annotated Guide to Sources, by  
Bausell RB, 178  
Biometrie in der Chemisch-  
Pharmazeutischen Industrie 4.  
Stand und Perspektiven, ed. Volmar  
J, 517  
Data Collection Forms in Clinical Trials,  
by Spilker B, Schoenfelder J, 351  
Methodological Errors in Medical  
Research, by Andersen B, 91  
Methodological Issues in AIDS Clinical  
Trials, Volume 3, Supplement 2,  
1990. Issue of *Journal of Acquired  
Immune Deficiency Syndromes*, eds.  
Ellenberg S, Kahn JO, 513  
Principles of Medical Statistics, 12th Ed.,  
by Hill AB, Hill ID, 515  
Sample Size Methodology, by Desu MM,  
Raghavarao D, 519  
Treatment of Early Breast Cancer, Volume  
I. Worldwide Evidence 1985-1990,  
by Early Breast Cancer Trialists'  
Collaborative Group, 250

### BRONCHIAL ASTHMA

Recruiting Children and Their Families for  
Clinical Trials: A Case Study, 315

### CARDIA

Distributed Data Analysis in a Multicenter  
Study: The CARDIA Study, 80

- Quality Control of Dietary Data Collection in the CARDIA Study, 156
- CAROTID ATHEROSCLEROSIS**  
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495  
Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293
- CENSORING**  
A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148
- CHILDREN**  
Recruiting Children and Their Families for Clinical Trials: A Case Study, 315
- CHOLESTEROL**  
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495  
A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122
- CLINICAL FACTORS**  
Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40
- CLINICAL TRIALS**  
Access to Data: A Contemporary Direction for Clinical Trials, 93  
AIDS and the Ethics of Clinical Trials: Learning the Right Lessons, 1  
Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226  
Clinical Trials of Informed Consent, 321  
Enrollment in Clinical Trial: Institutional Factors Affecting Enrollment in the Cardiac Arrhythmia Suppression Trial (CAST), 466  
The Future of Statistics and Statisticians in European Regulatory Affairs, 459  
The Impact of Automated Blood Pressure Devices on the Efficiency of Clinical Trials, 240  
Overrunning and Underrunning in Sequential Clinical Trials, 106  
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495  
Recruiting Children and Their Families for Clinical Trials: A Case Study, 315  
Regulatory Process Affects Clinical Trial Registration in Spain, 507  
Studies of Ocular Complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, Design, and Methods, 22  
Studying Treatments for AIDS: New Challenges for Clinical Trials—A Panel Discussion at the 1990 Annual Meeting of the Society for Clinical Trials, 272  
Vicissitudes in Clinical Trial Research: Subjects, Participants, Patients, 185  
Why Register Clinical Trials?—Revisited, 170
- CLUSTER RANDOMIZATION**  
Aspects of Statistical Design for the Community Intervention Trial for Smoking Cessation (COMMIT), 6
- COMMUNITY STUDIES**  
Aspects of Statistical Design for the Community Intervention Trial for Smoking Cessation (COMMIT), 6
- COMPARATIVE TRIALS**  
The Impact of Automated Blood Pressure Devices on the Efficiency of Clinical Trials, 240  
Sample Size Determination Based on Fisher's Exact Test for Use in 2 x 2 Comparative Trials with Low Event Rates, 134
- COMPOSITE OUTCOME**  
A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148
- COMPREHENSIVE COHORT FOLLOW-UP STUDY**  
Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226
- CONDITIONAL POWER**  
Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62



**CONTROLLED CLINICAL TRIALS**

Recruitment Strategies in the Studies of Left Ventricular Dysfunction (SOLVD): Strategies for Screening and Enrollment in Two Concurrent but Separate Trials, 325

**COORDINATING CENTERS**

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80

**COX'S PROPORTIONAL HAZARDS REGRESSION MODEL**

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

**CROSSOVER DESIGN**

A Note on the Three-Period Two-Treatment Crossover Design (letter), 248

**CUTOFF ASSIGNMENT STRATEGIES**

Cutoff Assignment Strategies for Enhancing Randomized Clinical Trials, 190

**CYTOMEGALOVIRUS RETINITIS**

Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial:  
1. Rationale, Design, and Methods, 22

**DATA ACQUISITION**

Access to Data: A Contemporary Direction for Clinical Trials, 93  
Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

**DATA ANALYSIS**

Impact of Random Assignment on Study Outcome: An Empirical Examination, 50

**DATA COLLECTION**

Quality Control of Dietary Data Collection in the CARDIA Study, 156

**DELAYED OBSERVATIONS**

Overrunning and Underrunning in Sequential Clinical Trials, 106

**DIETARY DATA COLLECTION**

Quality Control of Dietary Data Collection in the CARDIA Study, 156

**DISTRIBUTED DATA ANALYSIS**

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80

**DOUBLE DATA ENTRY**

Single vs. Double Data Entry in CAST, 487

**DRUG REGULATION**

The Future of Statistics and Statisticians in European Regulatory Affairs, 459

**EDITORIALS**

Access to Data: A Contemporary Direction for Clinical Trials, 93

**ENROLLMENT**

Enrollment in Clinical Trial: Institutional Factors Affecting Enrollment in the Cardiac Arrhythmia Suppression Trial (CAST), 466

**ERROR RATES**

Single vs. Double Data Entry in CAST, 487

**ETHICS**

AIDS and the Ethics of Clinical Trials:  
Learning the Right Lessons, 1  
Vicissitudes in Clinical Trial  
Research: Subjects, Participants, Patients, 185

**EXTERNAL VALIDITY**

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

**FISHER'S EXACT TEST**

Sample Size Determination Based on Fisher's Exact Test for Use in 2 x 2 Comparative Trials with Low Event Rates, 134

**FOLLOW-UP**

Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

**FOSCARNET**

Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial: 1.  
Rationale, Design, and Methods, 22

**FRANCIS, THOMAS, JR.**

Remembering the Role of Thomas Francis, Jr. in the Design of the 1954 Salk Vaccine Trial, 181

**GANCICLOVIR**

Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial:  
1. Rationale, Design, and Methods,  
22

**GROUP RANDOMIZATION**

Aspects of Statistical Design for the  
Community Intervention Trial for  
Smoking Cessation (COMMIT), 6

**HEART FAILURE, CONGESTIVE**

Congestive Heart Failure: Survival Trial of  
Antiarrhythmic Therapy (CHF  
STAT), 339  
Recruitment Strategies in the Studies of  
Left Ventricular Dysfunction  
(SOLVD): Strategies for Screening  
and Enrollment in Two Concurrent  
but Separate Trials, 325

**HILL, AUSTIN BRADFORD (SIR)**

Sir Austin Bradford Hill: An Appreciation,  
100

**HYPERCHOLESTEROLEMIA**

A Sequential Procedure for a Phase II  
Efficacy Trial in  
Hypercholesterolemia, 122

**HYPERTENSION**

The Impact of Automated Blood Pressure  
Devices on the Efficiency of Clinical  
Trials, 240

**IMPUTATION**

A Test for the Difference Between Two  
Treatments in a Continuous  
Measure of Outcome When There  
Are Dropouts, 213

**INACTIVE STATUS**

Patient and Clinical Factors Predictive of  
Missed Visits and Inactive Status in  
a Multicenter Clinical Trial, 40

**INFORMED CONSENT**

Clinical Trials of Informed Consent, 321

**INTERPRETATION**

Impact of Random Assignment on Study  
Outcome: An Empirical  
Examination, 50

**INTIMA-MEDIA THICKNESS**

Pravastatin, Lipids, and Atherosclerosis in  
the Carotid Arteries: Design

Features of a Clinical Trial with  
Carotid Atherosclerosis Outcome,  
495

**KEEPING POSTED**

Regulatory Process Affects Clinical Trial  
Registration in Spain, 507  
Why Register Clinical Trials?—Revisited,  
170

**KEY DATA ENTRY**

Single vs. Double Data Entry in CAST, 487

**LDL CHOLESTEROL**

Pravastatin, Lipids, and Atherosclerosis in  
the Carotid Arteries: Design  
Features of a Clinical Trial with  
Carotid Atherosclerosis Outcome,  
495

**LETTERS TO THE EDITOR**

A Note on the Three-Period Two-  
Treatment Crossover Design, 248

**LIKELIHOOD RATIOS**

Termination of a Clinical Trial With No  
Treatment Group Difference: The  
Lupus Nephritis Collaborative  
Study, 62

**LIPID-LOWERING**

Rationale and Design for the  
Asymptomatic Carotid Artery  
Plaque Study (ACAPS), 293

**LONGRANK TEST**

Exemplary Data: Sample Size and Power  
in the Design of Event-Time Clinical  
Trials, 256

**MANN-WHITNEY TEST**

A Test for the Difference Between Two  
Treatments in a Continuous  
Measure of Outcome When There  
Are Dropouts, 213

**MATCHING**

Aspects of Statistical Design for the  
Community Intervention Trial for  
Smoking Cessation (COMMIT), 6

**MEDICAL PRACTICE**

Doctoring: From Art to Engineering, 97

**MISSED VISITS**

Patient and Clinical Factors Predictive of  
Missed Visits and Inactive Status in  
a Multicenter Clinical Trial, 40

**MULTICENTER CLINICAL TRIALS**

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80  
Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

**NONRESPONSE**

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213

**NONSTOCHASTIC DATA**

Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

**OBITUARY**

Sir Austin Bradford Hill: An Appreciation, 100

**OPHTHALMOLOGY**

Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial:  
1. Rationale, Design, and Methods, 22

**OVERRUNNING**

Overrunning and Underrunning in Sequential Clinical Trials, 106

**PARAMETERIZATION**

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

**PATIENT FACTORS**

Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

**PATIENT PARTICIPATION**

Recruitment Strategies in the Studies of Left Ventricular Dysfunction (SOLVD): Strategies for Screening and Enrollment in Two Concurrent but Separate Trials, 325

**PEER REVIEW**

Editorial Peer Review: Let Us Put It On Trial, 443

**PHASE II**

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

**PHI CORRELATION**

Sample Size Determination Under an Exponential Model in the Presence of a Confounder and Type I Censoring, 446

**PHYSICIAN'S ROLES**

Doctoring: From Art to Engineering, 97

**POWER**

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148  
Sample Size Determination Under an Exponential Model in the Presence of a Confounder and Type I Censoring, 446  
Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

**QUALITY CONTROL**

Quality Control of Dietary Data Collection in the CARDIA Study, 156

**RANDOM ASSIGNMENT**

Impact of Random Assignment on Study Outcome: An Empirical Examination, 50

**RANDOMIZED CLINICAL TRIALS**

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226  
Cutoff Assignment Strategies for Enhancing Randomized Clinical Trials, 190  
Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

**RANKING**

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148

**RECRUITMENT**

Recruiting Children and Their Families for Clinical Trials: A Case Study, 315

**RECRUITMENT PERIOD**

Sample Size Determination Under an Exponential Model in the Presence



of a Confounder and Type I  
Censoring, 446

#### **REDUCTASE INHIBITORS**

Pravastatin, Lipids, and Atherosclerosis in  
the Carotid Arteries: Design  
Features of a Clinical Trial with  
Carotid Atherosclerosis Outcome,  
495

#### **REGISTERS OF CLINICAL TRIALS**

Why Register Clinical Trials?—Revisited,  
170

#### **REGISTRATION**

Regulatory Process Affects Clinical Trial  
Registration in Spain, 507

#### **REGULATORY AFFAIRS**

The Future of Statistics and Statisticians in  
European Regulatory Affairs, 459  
Regulatory Process Affects Clinical Trial  
Registration in Spain, 507

#### **RESEARCH DESIGN**

Impact of Random Assignment on Study  
Outcome: An Empirical  
Examination, 50

#### **RETINITIS**

Studies of Ocular Complications of AIDS  
Foscarnet-Ganciclovir  
Cytomegalovirus Retinitis Trial: 1.  
Rationale, Design, and Methods, 22

#### **SALK VACCINE TRIAL**

Remembering the Role of Thomas Francis,  
Jr. in the Design of the 1954 Salk  
Vaccine Trial, 181

#### **SAMPLE SIZE**

Sample Size Determination Based on  
Fisher's Exact Test for Use in 2 x 2  
Comparative Trials with Low Event  
Rates, 134

Sample Size Determination Under  
an Exponential Model in the  
Presence of a Confounder and Type  
I Censoring, 446

#### **SCORING**

A Method for Assigning Scores to the  
Components of a Composite  
Outcome: An Example from the  
MITI Trial, 148

#### **SEQUENTIAL ANALYSIS**

Termination of a Clinical Trial With No

Treatment Group Difference: The  
Lupus Nephritis Collaborative  
Study, 62

#### **SEQUENTIAL CLINICAL TRIALS**

Overrunning and Underrunning in  
Sequential Clinical Trials, 106  
A Sequential Procedure for a Phase II  
Efficacy Trial in  
Hypercholesterolemia, 122

#### **SMOKING PREVALENCE**

Aspects of Statistical Design for  
the Community Intervention  
Trial for Smoking Cessation  
(COMMIT), 6

#### **SOCIETY FOR CLINICAL TRIALS**

Annual Meetings, 1992-1996, 92  
Fourteenth Annual Meeting of the Society  
for Clinical Trials, 353  
Officers—Board of Directors 1992-1993,  
354  
Studying Treatments for AIDS: New  
Challenges for Clinical Trials—A  
Panel Discussion at the 1990 Annual  
Meeting of the Society for Clinical  
Trials, 272  
Thirteenth Annual Meeting of the Society  
for Clinical Trials, 356

#### **STOCHASTIC CURTAILING**

Termination of a Clinical Trial With No  
Treatment Group Difference: The  
Lupus Nephritis Collaborative  
Study, 62

#### **STOPPING RULES**

Overrunning and Underrunning in  
Sequential Clinical Trials, 106

#### **SUDDEN DEATH**

Congestive Heart Failure: Survival Trial of  
Antiarrhythmic Therapy (CHF  
STAT), 339

#### **SURVIVAL**

Congestive Heart Failure: Survival Trial of  
Antiarrhythmic Therapy (CHF  
STAT), 339

#### **SUSPENDED JUDGMENT**

AIDS and the Ethics of Clinical Trials:  
Learning the Right Lessons, 1  
Clinical Trials of Informed Consent, 321  
Doctoring: From Art to Engineering, 97  
Editorial Peer Review: Let Us Put It On  
Trial, 443

Remembering the Role of Thomas Francis, Jr. in the Design of the 1954 Salk Vaccine Trial, 181

Thrombolytic Therapy for Acute Myocardial Infarction in the United States: We Started on the High Road, 253

#### **TERMINATION**

Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

#### **THROMBOLYTIC THERAPY**

Thrombolytic Therapy for Acute Myocardial Infarction in the United States: We Started on the High Road, 253

#### **TIMED EVENTS**

Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

#### **TRIANGULAR TEST**

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

#### **TWO-SAMPLE TEST**

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213

#### **ULTRASONOGRAPHY**

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495

Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

#### **UNDERRUNNING**

Overrunning and Underrunning in Sequential Clinical Trials, 106

#### **VENTRICULAR ARRHYTHMIA**

Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF STAT), 339

#### **WITHDRAWALS**

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213